Sunday, May 11, 2025
5/11/2025
Role of PAPP-A in Graves' Ophthalmopathy - PROJECT SUMMARY Graves’ Ophthalmopathy (GO) is the most serious extra-thyroidal complication that develops in patients with autoimmune Graves’ hyperthyroidism. It is characterized by increased orbital fat volume and extra-ocular muscle within the unyielding bony orbit, which can have deleterious consequences on eye function. Orbital decompression surgery is an effective but invasive treatment used for severe GO. A better understanding of the pathological mechanisms underlying GO may identify novel targets to inhibit the development and progression of GO before any clinical manifestation. Insulin-like growth factor-I receptor (IGF-IR) signaling has been found to be essential in promoting GO pathogenesis. A monoclonal antibody that binds to and blocks IGF-IR signaling, was recently FDA-approved for treatment of GO. However, adverse events have been documented, all likely due to the ubiquitous nature of IGF-IR. A better understanding of IGF signaling and its regulation in orbital tissue is needed to fully understand mechanism and avoid/reduce off-target consequences. One approach would be to target modifiers of IGF-IR signaling, instead of the IGF-IR per se. We propose PAPP-A as such a target. PAPP-A is a novel zinc metalloprotease that can increase pericellular IGF bioavailability through cleavage of inhibitory IGF binding proteins, in particular IGFBP-4. Conversely, inhibition of PAPP-A expression or its proteolytic activity represents an innovative approach to decrease IGF availability with resultant attenuation of IGF-IR signaling. Interestingly, the most potent stimulators of PAPP-A expression are pro-inflammatory cytokines, which are increased in orbital tissue from GO patients. We hypothesize that PAPP-A is a key modulator of IGF-R signaling in GO. Our Specific Aims are to: 1) Determine PAPP-A expression (basal and pro-inflammatory cytokine-induced) in orbital fibroblasts from GO patients and control subjects. 2) Determine the effect of a neutralizing monoclonal antibody that specifically inhibits PAPP-A- mediated IGFBP-4 proteolysis on IGF-I stimulated proliferation and differentiation in orbital fibroblasts from GO patients. We have primary fibroblasts from retro-orbital fat of GO patients at early passage in-hand and the experience with culture and analyses to establish feasibility. Preliminary results support a role for PAPP-A in GO. We anticipate outcomes from the proposed experiments that could ultimately lead to a novel targeted therapy for patients with GO.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).